Once-daily formulation provides 24-hour relief
of seasonal allergy symptoms with nasal congestion
BRIDGEWATER, N.J., July 27 /PRNewswire-FirstCall/ -- Sanofi-aventis
announced today that Allegra-D(R) 24 Hour (fexofenadine HCl 180
mg/pseudophedrine HCl 240 mg) Extended-Release Tablets are now available for
the treatment of seasonal allergy symptoms with nasal congestion in adults and
children 12 years of age and older. Allegra-D 24 Hour provides allergy
patients with the power of once-daily Allegra (fexofenadine HCl) 180 mg,
combined with 24-hour relief from nasal congestion, in a convenient, once-
daily tablet. Allegra-D 24 Hour is an addition to the Allegra(R) family of
non-sedating and non-impairing products available for the treatment of
seasonal allergy symptoms.
More than 40 million adults and children in the United States suffer from
seasonal allergies and associated symptoms, such as nasal congestion, watery
eyes, runny nose, sneezing and itchy throat. In fact, 9 out of 10 allergy
patients experience congestion and consider it the most frustrating symptom.
These symptoms are caused by the body's reaction to allergens and typically
occur in the spring and fall when large amounts of allergens, such as pollen,
are in the air.
Allegra-D 24 Hour utilizes a controlled-release technology that provides a
smooth delivery of pseudoephedrine over the entire dosing period, providing
24-hour nasal congestion relief in a convenient once-a-day dosage.
About Allegra Line of Products
Allegra offers an extensive family of products to provide patients with
greater convenience and flexibility in treating their different seasonal
allergy needs (Allegra 30 mg and 60 mg twice daily, Allegra 180 mg once daily,
Allegra-D 12 Hour (fexofenadine HCl 60 mg/ pseudoephedrine HCl 120 mg)
Extended-Release Tablets [for twice daily dosing] and Allegra-D 24 Hour).
The side effects with Allegra 180 mg for seasonal allergies are low and
may include headache, cold or back pain. The side effects for Allegra 60 mg
for seasonal allergies are low; less than 3% of people experience cold or flu,
nausea, menstrual pain or drowsiness. The side effects for Allegra 30 mg are
low and may include headache, cold, coughing or accidental injury.
Side effects with Allegra-D 12 Hour and Allegra-D 24 Hour were similar to
Allegra 60 mg alone (headache, insomnia or nausea) and Allegra 180 mg alone
(headache, cold or backache) respectively. Due to the decongestant
(pseudoephedrine) component in both Allegra-D 12 Hour and Allegra-D 24 Hour,
these products must not be used if you: are taking an MAO inhibitor (a
medication for depression) or have stopped taking an MAO inhibitor within 14
days; retain urine; have narrow-angle glaucoma; have severe high blood
pressure or severe heart disease. Side effects with pseudoephedrine may
include nervousness, restlessness, dizziness, or insomnia. Headache,
drowsiness, increased heart rate, palpitations, increased blood pressure, and
abnormal heart rhythms have been reported. You should also tell your doctor
if you have high blood pressure, diabetes, heart disease, glaucoma, thyroid
disease, impaired kidney function, or symptoms of an enlarged prostate such as
difficulty urinating.
For Allegra product information please log onto:
http://www.aventis-us.com/PIs/allegra_TXT.html .
For Allegra-D 12 Hour product information please log onto:
http://www.aventis-us.com/PIs/allegra_d_TXT.html .
For Allegra-D 24 Hour product information please log onto:
http://www.aventis-us.com/PIs/allegrad24.pdf .
About sanofi-aventis
The sanofi-aventis Group is the world's third largest pharmaceutical
company, ranking number one in Europe. Backed by a world-class R&D
organization, sanofi-aventis is developing leading positions in seven major
therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases,
central nervous system, internal medicine, and vaccines. The sanofi-aventis
Group is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Forward Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995. Forward-looking statements
are statements that are not historical facts. These statements include
financial projections and estimates and their underlying assumptions,
statements regarding plans, objectives and expectations with respect to future
operations, products and services, and statements regarding future
performance. Forward-looking statements are generally identified by the words
"expect," "anticipates," "believes," "intends," "estimates," "plans" and
similar expressions. Although sanofi-aventis' management believes that the
expectations reflected in such forward-looking statements are reasonable,
investors are cautioned that forward-looking information and statements are
subject to various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of sanofi-aventis, that could cause
actual results and developments to differ materially from those expressed in,
or implied or projected by, the forward-looking information and statements.
These risks and uncertainties include those discussed or identified in the
public filings with the SEC and the AMF made by sanofi-aventis, including
those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-
Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year
ended December 31, 2004. Other than as required by applicable law, sanofi-
aventis does not undertake any obligation to update or revise any forward-
looking information or statements.
Sanofi-aventis Group subsidiaries in the United States include Sanofi-
Synthelabo Inc., Aventis Pharmaceuticals Inc. and Sanofi Pasteur Inc.
Contact: Melissa Feltmann
908.243.7080
Melissa.feltmann@sanofi-aventis.com
SOURCE sanofi-aventis Group
 back to top
Related links:
http://www.sanofi-aventis.com
Company News On-Call:
http://www.prnewswire.com/comp/232375.html
CONTACT:
Melissa Feltmann, +1-908-243-7080,
Melissa.feltmann@sanofi-aventis.com
|
